Sodium fluoride - Mission Pharmacal

Drug Profile

Sodium fluoride - Mission Pharmacal

Alternative Names: Fluoride - Mission Pharmacal; Neosten; Slow Fluoride; SR-NaF

Latest Information Update: 04 Feb 2008

Price : $50

At a glance

  • Originator Mission Pharmacal; University of Texas Southwestern Medical Center
  • Class Fluorides; Osteoporosis therapies
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 02 May 2005 No development reported - Preregistration for Postmenopausal osteoporosis in USA (PO)
  • 22 May 2000 Registered for Postmenopausal osteoporosis in Germany (PO)
  • 10 Feb 1999 Preregistration for Postmenopausal osteoporosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top